Literature DB >> 14506155

Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.

Lin Wang1, Ashraful Hoque, Robert Z Luo, Jiuhong Yuan, Zhen Lu, Arata Nishimoto, Jinsong Liu, Aysegul A Sahin, Scott M Lippman, Robert C Bast, Yinhua Yu.   

Abstract

PURPOSE: Ductal carcinoma in situ (DCIS) is a preinvasive-stage breast carcinogenesis that accounts for approximately 20 approximately 25% of mammographically detected breast cancers. A significant fraction of untreated DCIS will evolve into invasive cancer. ras homologue I (ARHI) is an imprinted tumor suppressor gene that is expressed in normal breast epithelial cells but absent or down-regulated in breast cancer cells. This study investigated the relationship of ARHI expression to the progression of breast cancer. EXPERIMENTAL
DESIGN: We analyzed ARHI expression in DCIS, invasive breast carcinoma, and adjacent normal breast epithelium from 64 formalin-fixed, paraffin-embedded DCIS specimens by both immunohistochemistry and in situ hybridization. We also analyzed the correlation between ARHI expression and progression of breast cancer, as well as the correlation of ARHI expression and cyclin D1 and p21(WAF1/CIP1) expression in DCIS.
RESULTS: Normal breast epithelium was found in all of the specimens and invasive breast carcinoma was found in 23 specimens. ARHI mRNA and protein were detected in all of the normal breast epithelia. ARHI expression was detected mainly in cytoplasm and rarely present in the nucleus. By histochemical analysis, ARHI expression was down-regulated in 41% (26 of 64) of DCIS and 70% (16 of 23) of invasive carcinomas comparing the specimens with adjacent normal breast epithelium. When DCIS and invasive cancer were present in the same sample, ARHI was further down-regulated in 26% (6 of 23) of invasive carcinoma. In four cases [4 (17%) of 23] of invasive carcinoma, ARHI protein expression was totally lost. Consistent results were obtained with an in situ hybridization assay for ARHI at the mRNA level. Higher levels of expression of cyclin D1 and p21(WAF1/CIP1) were observed in DCIS than in the adjacent epithelia. The expression of cyclin D1 and p21(WAF1/CIP1) was inversely correlated with that of ARHI.
CONCLUSIONS: Our results indicate that ARHI expression is markedly down-regulated in DCIS, and a further decrease in ARHI expression is associated with progression of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14506155

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  26 in total

1.  MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer.

Authors:  Yi Chen; Mohd Saif Zaman; Guoren Deng; Shahana Majid; Shranjot Saini; Jan Liu; Yuichiro Tanaka; Rajvir Dahiya
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-11

2.  Somatic Mutation of ARHI Gene in Hepatocellular Carcinomas.

Authors:  Chang Jae Kim; Jung Woo Shin; Seok Won Jung; Bo Ryung Park; Neung Hwa Park
Journal:  Pathol Oncol Res       Date:  2015-07-05       Impact factor: 3.201

3.  RAS-related GTPases DIRAS1 and DIRAS2 induce autophagic cancer cell death and are required for autophagy in murine ovarian cancer cells.

Authors:  Margie N Sutton; Hailing Yang; Gilbert Y Huang; Caroline Fu; Michael Pontikos; Yan Wang; Weiqun Mao; Lan Pang; Maojie Yang; Jinsong Liu; Jan Parker-Thornburg; Zhen Lu; Robert C Bast
Journal:  Autophagy       Date:  2018-03-21       Impact factor: 16.016

4.  The tumor suppressor DiRas3 forms a complex with H-Ras and C-RAF proteins and regulates localization, dimerization, and kinase activity of C-RAF.

Authors:  Angela Baljuls; Matthias Beck; Ayla Oenel; Armin Robubi; Ruth Kroschewski; Mirko Hekman; Thomas Rudel; Ulf R Rapp
Journal:  J Biol Chem       Date:  2012-05-17       Impact factor: 5.157

5.  Low expression of ARHI is associated with shorter progression-free survival in pancreatic endocrine tumors.

Authors:  Irene Dalai; Edoardo Missiaglia; Stefano Barbi; Giovanni Butturini; Claudio Doglioni; Massimo Falconi; Aldo Scarpa
Journal:  Neoplasia       Date:  2007-03       Impact factor: 5.715

6.  Imprinted chromatin around DIRAS3 regulates alternative splicing of GNG12-AS1, a long noncoding RNA.

Authors:  Malwina Niemczyk; Yoko Ito; Joanna Huddleston; Anna Git; Sayeda Abu-Amero; Carlos Caldas; Gudrun E Moore; Lovorka Stojic; Adele Murrell
Journal:  Am J Hum Genet       Date:  2013-07-18       Impact factor: 11.025

7.  DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells.

Authors:  Zhen Lu; Maria T Baquero; Hailing Yang; Maojie Yang; Albert S Reger; Choel Kim; Douglas A Levine; Charlotte H Clarke; Warren S-L Liao; Robert C Bast
Journal:  Autophagy       Date:  2014-06       Impact factor: 16.016

8.  The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells.

Authors:  Zhen Lu; Robert Z Luo; Yiling Lu; Xuhui Zhang; Qinghua Yu; Shilpi Khare; Seiji Kondo; Yasuko Kondo; Yinhua Yu; Gordon B Mills; Warren S-L Liao; Robert C Bast
Journal:  J Clin Invest       Date:  2008-11-20       Impact factor: 14.808

9.  Autophagy-induced tumor dormancy in ovarian cancer.

Authors:  Ravi K Amaravadi
Journal:  J Clin Invest       Date:  2008-11-20       Impact factor: 14.808

10.  Loss of epigenetic Kruppel-like factor 4 histone deacetylase (KLF-4-HDAC)-mediated transcriptional suppression is crucial in increasing vascular endothelial growth factor (VEGF) expression in breast cancer.

Authors:  Alpana Ray; Mohamed Alalem; Bimal K Ray
Journal:  J Biol Chem       Date:  2013-08-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.